19 March 2019 Alembic Pharmaceuticals ALPMs capex investment has seen a significant increase from INR8.8b gross block in FY15 to INR11b over FY15-19E, which the company used to aggressively tap business opportunities in its key focus market, the US. But, due to its (a) track record of healthy launches, (b) ability to grab product-specific opportunities supported by a nimble supply chain, and (c) strong pipeline of products under development filings, ALPM remains confident of scaling the US business over the next 3-4 years. ALPM has about 190 projects under development Oral solids (~40-45%), Derma (~28%), and the remaining Onco-Injectables/general injectables. ALPM would be filing through the CB30 route to transfer a few products from its existing formulation unit at Panelav to a new unit at Jarod. ALPM has about 20 injectables (onco products) under development at its with exhibit batches planned in 2QFY20. It has about 20 Oral solids under development; exhibit batches have already commenced for a few products.